The global chronic inflammatory demyelinating polyneuropathy market expected to grow 6.45 % between 2019 and 2026

 


The global chronic inflammatory demyelinating polyneuropathy (CIDP) market is expected to grow at a 6.45 percent CAGR between 2019 and 2026.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder that can lead to paralysis (impairment of sensory function in limbs). It is caused by inflammation of the nerve roots and peripheral nerves, as well as the destruction of the fatty protective covering (myelin sheath) over the nerves. It slows the transmission of nerve signals, resulting in nerve fiber destruction. Corticosteroids alone or in combination with an immunosuppressant, plasma exchange, and intravenous immunoglobulin therapy can be used to treat it.

According to the most recent report, increasing drug approvals by regulatory authorities will drive the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market. For example, in March 2017, CSL Behring received FDA approval for Privigen, an immunoglobulin therapy for the treatment of chronic inflammatory demyelinating polyneuropathy.

Furthermore, CSL Behring received FDA approval for Hizentra, a type of subcutaneous immunoglobulin therapy that prevents relapsing neuromuscular disability, in March 2018. It provides a convenient treatment method in which patients can self-infuse. The approval was based on the clinical trial's phase III results.

 Several potential drugs for the treatment of chronic inflammatory demyelinating polyneuropathy are in the works (CIDP). Shire Plc, for example, began clinical trials of HyQvia in January 2016 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HyQvia is an intravenous immunoglobulin therapy that has been approved for the treatment of primary immunodeficiency and is currently in phase III clinical trials for CIDP. As a result, the successful completion of clinical trials and subsequent launch of these products is expected to boost the global market growth. The introduction of advanced technologies in diagnostic tools for chronic inflammatory demyelinating polyneuropathy (CIDP) is expected to accelerate global market growth.

North America is expected to be the global leader in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Initiatives from governments and other organizations are expected to have an impact on the growth of the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market. As an example, The Guillain-Barre syndrome and Chronic Inflammatory Demyelinating Polyneuropathy (GBS | CIDP) the international foundation announced in April 2019 that May will be designated as GBS | CIDP awareness month.

The failure of drugs in late-stage clinical trials has hampered the growth of the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market. For example, drugs indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) such as Fingolimod (Gilenya, Novartis AG) and Acthar gel (Mallinckrodt Pharmaceuticals) failed in clinical trials in 2016 and 2018, respectively. These failures were linked to serious side effects caused by these medications, such as hypertension.

CSL Behring, Kedrion S.p.A., Takeda Pharmaceutical Co. Ltd., Shire Plc., GeNeuro SA, Baxter International Inc., Octapharma AG and Grifols S.A., Teijin Pharma Ltd., and Nihon Pharmaceutical Co. Ltd. are some of the major players in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market.

Comments

Post a Comment

Popular posts from this blog

Quaternary Ammonium Compounds Market to Grow at USD 1.63 billion by 2027: COVID Impact & Post COVID Analysis, Business Opportunities, and Strategies

Image
  By 2027, the global market for Quats (Quaternary Ammonium Compounds) is expected to reach USD 1.63 billion. The market is being driven by the rise in the occurrence of hospital-acquired infections (HAIs) and the implementation of stringent regulations and favorable government initiatives on disinfection and sterilization. Developing economies are expected to give significant opportunities for growth. Fabric softeners, disinfectants, surfactants, antistatic agents, and wood preservation are just a few of the uses for quaternary ammonium compounds. The product's numerous applications are projected to raise demand shortly. Quaternary ammonium compounds are commonly employed as conditioning agents in personal care products, such as skin, textile, and hair softeners. The surfactant industry considers QACs to be the ultimate workhorse. They're on the USEPA's "High Production Volume Chemicals" list. Self-assembly, surface-active properties, detergency, and antibact...
Read more

Butyraldehyde Market Trends, Growth, Demand, opportunities, Scope & Forecast 2027 by CMI

Image
  Buthylaldehyde (also known as butanal) is a 4-carbon aldehyde that is used as a building block in organic syntheses to make various products such as n-butanol, 2-ethyl hexanol, 2-ethyl hexanoic acid, trimethylolpropane, and polyvinyl butyral. Pharmaceuticals, agrochemicals, antioxidants, textile auxiliaries, perfumes, flavors, and many forms of additives are all made with it as an intermediate (fillers, wetting agents, defoaming agents, improvers). Alcohols (mono- and multi-hydroxide), acids, amines, and esters are all made from N-butyraldehyde as a raw material. Rubber accelerators, synthetic resins, plasticizers, solvents, and high molecular weight polymers are the biggest uses of butyraldehyde. All of these buthylaldehyde applications are detailed in this study. Butyraldehyde is widely used as a starting material for the downstream organic synthesis of n-butanol, trimethylolpropane, 2-ethyl hexanoic acid, and polyvinyl butyral. Pharmaceutical intermediates, synthetic resins,...
Read more

Glass Mat Thermoplastic Market : Size, Growth, Regional Analysis, And Market Area

Image
Glass mat thermoplastic is a thermoplastic that can be easily moulded and is used to make a variety of components, primarily in the automotive industry. Because of the longer residual length of the glass strands, glass mat thermoplastic has better mechanical properties than injection moulded reinforced thermoplastic. It is primarily used as a replacement for steel and aluminium. They are available in panel form as well as 3D structural component form. Furthermore, they are a lightweight material with a low relative density, excellent hardness and rigidity at low temperatures, and are chemical and moisture resistant . These are durable materials with ease of recyclability. Furthermore, the demand for the glass mat thermoplastic material from the automobile and aeration industries leads to market growth. When compared to other end-use industries, the automotive application segment is expected to remain the largest. Furthermore, a surge in government initiatives for increased fuel eco...
Read more